State Government Relations

BIOtechNOW’s Tracy Cooley talks to Dr. Schubert of the  Bioscience Association of West Virginia about biotech in West Virginia – major areas of growth, the outlook for growth of the industry within the states, and plans for the upcoming  BIO International Convention.

Tracy Cooley talks to Renee Winsky about biotech in Maryland and the upcoming  BIO International Convention  in Washington, DC.

Despite the fact that U.S. Secretary of Agriculture Tom Vilsack believes that the regulation of genetically engineered agricultural products must be science-based, and that he has “no doubts about the safety of the products this system has approved and will continue to approve,” some state legislatures are considering bills requiring labeling for biotech-derived food. These bills defy existing science-based regulation and are wholly unnecessary.

You might have heard that the Prince of Wales, just days after hosting the Royal Wedding, paid us a visit here in Washington.  Prince Charles, a long-time organic food advocate and self-described environmentalist, was here to speak at a Washington Post symposium on the Future of Food.

VABIO's Mark Herzog discusses biotech in Virginia and the upcoming BIO International Convention in Washington, DC.

Mark Herzog, executive director of the Virginia Biotechnology Association recently discussed the success and challenges facing the burgeoning bioscience industry in his state.

Recently the Oklahoma Bioscience Association held a 2011 BIO International Convention information session for their delegates to get ready for the June event.

The Maryland initiative’s 10-year plan helps build biotech access to funding

BIOtechNow’s Tracy Cooley discusses biotech in West Virginia – major growth areas, outlook for the future, and upcoming plans for the BIO International Convention – with Derek Gregg.

Derek Gregg discusses biotech in WV – major growth areas, outlook for the future, and upcoming plans for the BIO International Convention.

The Massachusetts Life Sciences Center, which is tasked with administering the $1 billion state's life sciences initiative, has awarded five loans to start up companies, totaling $3.75 million.

Budget victories will help biotechnology in the Commonwealth

The U.S. bioscience industry continued to score employment gains through 2008 - the first year of the recent economic downturn, according to a study released today by Battelle and the Biotechnology Industry Organization (BIO).

January 21 2014
BIO's Senior Policy Consultant, Peter Pellerito, testified before the Michigan Legislature's Bioscience Caucus on economic development initiatives that support the growth of the bioscience industry.
September 17 2013
Fritz Bittenbender, Senior Vice President of External Affairs, delivered testimony supporting a pathway for patients to access lower cost interchangeable biological products.
May 8 2013
BIO  urges Florida Governor Scott to sign House Bill 365 – a bill related to the substitution of biologic and biosimilar medicines – which recently passed out of the Legislature.
February 1 2013
BIO supports passage of Florida House Bill 365, which provides requirements for pharmacist to dispense substitute biological products that are determined to be interchangeable for prescribed biological product.
January 24 2013
To ensure transparency and communication between patients and their treatment teams, BIO believes that certain safeguards should guide substitution policies for interchangeable biologics under state law as well.
April 10 2014
BIO and Delaware Bio commend the Delaware State Senate for unanimously passing legislation yesterday designed to create a pathway for the substitution of interchangeable biologic medicines. 
March 25 2014
The Biotechnology Industry Organization (BIO) and the Indiana Health Industry Forum (IHIF) commend Indiana Governor Mike Pence for signing legislation today designed to create a pathway for the substitution of interchangeable biologic medicines.
January 22 2014
BIO and WBBA commend the Washington State House and Senate for continuing to advance legislation designed to create a pathway for the substitution of interchangeable biologic medicines.
November 13 2013
The Pennsylvania Senate Public Health and Welfare Committee approved Senate Bill 405, which would require a pharmacist to notify the patient and, within 72 hours, the patient’s physician of any biologic product substitution.
October 22 2013
Pending Legislation will Protect Indiana Citizens Utilizing Biologic Medications to Manage Chronic Diseases and other Unmet Medical Needs